Add the PROPEL family of implants to your ACTION plan
The PROPEL family of implants offers 3 steroid-eluting implants under one brand, allowing ENTs to select the best option that conforms to the anatomical needs of their patients1,2
MF delivers the ideal combination of potency and safety
* Lipophilicity numbers normalized relative to triamcinolone acetonide.
† As measured by relative receptor binding affinity compared to dexamethasone, which is set to a value of 100. Higher values designate greater potency.
‡ As measured by plasma concentration of drug from intranasal vs intravenous route.
PROPEL implants are clinically proven to maintain patency and to locally deliver mometasone furoate to the sinus mucosa
- PROPEL is the only Sinus Surgery Device Backed by Level 1a Evidence11
- 35% Relative Reduction|| in the Need for Postoperative Intervention11
- Enhances Physician Choice: Small Size, Unique Hourglass Shape, Flexible Applicator
- 65% Relative ReductionII in Postoperative Intervention12-13
* Postoperative intervention is a composite of need for surgical interventions to separate adhesions and/or need to prescribe oral steroids for inflammation.
† Judged by an independent reviewer or independent panel.
‡ Judged by clinical investigators.
§ Secondary endpoints were not adjusted for multiplicity.
| P values adjusted for multiplicity.
|| All relative reductions Calculated as (T-C)/C as part of adhoc analysis.
PROPEL study design: Meta-analysis of two prospective, randomized, double-blinded multicenter studies (Pilot and ADVANCE II) that enrolled 143 patients.
- PROPEL [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2014.
- PROPEL Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
- PROPEL Contour [Instructions for use]. Menlo Park, CA: Intersect END; 2021.
- Food and Drug Administration. Approval Order. https://www.access-data.fda.gov/cdrh_docs/pdf10/P1000445018A.pdf. Accessed June 24, 2019.
- Li PM, Downie D, Hwang PH. Controlled steroid delivery via bioabsorbable stent: safety and performance in a rabbit model. Am J Rhinol Allergy.2009;23(6):591-596.
- Lemke T, Williams D, Roche V, Zito SW, eds. Foye’s Principles of Medicinal Chemistry. 6th ed. Balitmore, MD: Lippincott Williams & Wilkins; 2008.
- Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(4):356-363.
- Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Invenstig Allergol Clin Immunol. 2012:22(1):1-12.
- PubChem. Dexamethasone. https://pubchem.ncbi.nlm.nih.gov/compound/Dexamethasone. Accessed June 24, 2019.
- Hochhaus G. Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clin Ther. 2008:30(1):1-13.
- Han JK, Marple BF, Smith TL, et al. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. Int Forum Allergy Rhinol. 2012;2(4):271-279.
- Luong A, Ow RA, Singh A, et al. Safety and effectiveness of a bioabsorbable steroid-releasing implant for the paranasal sinus ostia: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2018;144(1):28-35.
- PROGRESS CSR, P500-0514, R28020, Rev 4.0, 28 December 2016.
- Murr AH, Smith TL, Hwang PH, et al. Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. Int Forum Allergy Rhinol. 2011;1(1):23–32.
Request an Intersect ENT representative
All fields required